Patterns of erythropoiesis-stimulating agent use for chemotherapy-induced anemia in lung cancer: Results of a retrospective Hungarian real-life clinical data analysis

Lilla Tamási, Veronika Müller, Noémi Eszes, Tamás Kardos, Marianna Budai, Krisztina Vincze, György Losonczy, Mária Szilasi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: Lung cancer carries a relatively high risk of chemotherapy-induced anemia, one of the most frequent hematological complications. Previous data show a lack of optimal anemia correction in patients with chemotherapy-induced anemia. This paper analyzes real-life data considering the prevalence and severity of chemotherapy-induced anemia, together with the frequency and efficacy of erythropoietin treatment of anemia in Hungarian lung cancer patients. Research design and methods: Data of 482 patients with histological or cytological confirmed lung cancer receiving chemotherapy were collected retrospectively between 1 January and 31 December, 2008. In all, 83 (17%) of them developed chemotherapy-induced moderate to severe anemia (44.6% male, 55.4% female; mean age 70 ± 8.6 years; NSCLC 67.5%, small cell lung cancer 32.5%). Results: More than 50% of the patients suffering from moderate to severe chemotherapy-induced anemia (hemoglobin below 10 g/dl) did not receive erythropoietin treatment. Chemotherapy had to be postponed due to anemia in 32.26% of the patients receiving erythropoietin supplementation, while this was seen in 41.94% of the group without erythropoietin treatment (p < 0.05). In patients not receiving erythropoietin, the severity of anemia increased, while erythropoietin treated patients maintained acceptable hemoglobin levels after the end of the chemotherapy. Conclusions: The data draws attention to the fact that nowadays chemotherapy-induced anemia is not treated according to current guidelines in many lung cancer cases in Hungary.

Original languageEnglish
Pages (from-to)503-507
Number of pages5
JournalExpert Opinion on Drug Safety
Volume10
Issue number4
DOIs
Publication statusPublished - Jul 1 2011

Keywords

  • chemotherapy-induced anemia
  • erythropoietin supplementation
  • hemoglobin concentration
  • treatment

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Patterns of erythropoiesis-stimulating agent use for chemotherapy-induced anemia in lung cancer: Results of a retrospective Hungarian real-life clinical data analysis'. Together they form a unique fingerprint.

  • Cite this